Leukemia, acute lymphocytic, susceptibility to, 1

This phase II trial is testing whether adding the drug asciminib to standard treatment can improve outcomes for people newly diagnosed with Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). The study will enroll 55 participants and involves several phases o…

This study tests a new way to treat adults with a specific type of leukemia (Ph+ ALL) that has come back or not responded to treatment. The approach combines low-intensity chemotherapy with two targeted drugs, ponatinib and blinatumomab, to kill cancer cells and boost the immune …

This study tested a combination of the immunotherapy drug blinatumomab with either standard chemotherapy or dasatinib and prednisone in adults aged 65 and older with acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve survival and control the …

This phase II trial is studying a combination of chemotherapy (Hyper-CVAD) and the targeted drug dasatinib, with or without a donor stem cell transplant, in 97 adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). The goal is to see how well this approa…

This study tests a software platform called Nest that helps young adults (ages 18-49) with inherited cancer risks manage their care. Participants will use the tool to track screening and share information with doctors and family. Researchers will compare users to non-users to see…

This phase I trial tests the safety of adding ruxolitinib to a standard combination of dasatinib and dexamethasone for adults aged 40 and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study starts with a low dose of ruxoli…

This phase 3 trial tests imatinib, a targeted cancer drug, with two different chemotherapy backbones in children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to see if a less intense chemo regimen works as well as the s…

This early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…

This study tests a powerful mix of chemotherapy drugs plus a targeted pill (ponatinib) for people with a fast-growing leukemia called Philadelphia chromosome-positive ALL. The goal is to see if this combination can stop the cancer from coming back. About 88 adults with newly diag…

This phase 2 trial tests whether adding blinatumomab (an immunotherapy) to standard targeted therapy (dasatinib) can improve treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The goal is to achieve a deep molecular response without…

This study tests a two-year follow-up program for 200 adults with hereditary cancer syndromes like BRCA or Lynch syndrome. Participants get personalized care plans and regular check-ins with a genetics doctor to help them follow cancer prevention and screening guidelines. The goa…

This phase 3 trial tests whether ponatinib (Iclusig) works better than imatinib (Gleevec) for adults newly diagnosed with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Both drugs are taken as pills alongside reduced-intensity chemotherapy for up to 20 m…

This early-stage study tests a treatment that uses a patient's own immune cells, modified to recognize and attack cancer cells, for adults with B-cell blood cancers that have returned or not responded to standard therapy. The treatment is given with chemotherapy and sometimes an …

This study is developing a blood test to find early-stage tumors in people with hereditary cancer syndromes (high genetic risk for cancer). Researchers will collect blood samples and medical data from about 1,400 participants across Canada. They will also interview patients and d…

This study looks at whether short educational videos can help people with inherited cancer gene mutations learn more about their condition. About 43 adults who carry mutations in genes like BRCA1 or BRCA2 will watch the videos and then take a quiz. The goal is to see if this simp…

This study is testing a chatbot and online portal called AYA-RISE to help adolescents and young adults (ages 12-24) who have genetic conditions that raise their cancer risk. The goal is to see if the tool helps them communicate with family and doctors and make informed decisions …

This study is creating a web-based program to help people with hereditary cancer mutations share their genetic test results with family members. The goal is to increase awareness among at-risk relatives so they can take steps to prevent cancer. The program is designed for patient…

This study tests two simple, scalable methods to help people with inherited cancer risk follow through on recommended screenings. Researchers will provide online educational resources and personalized phone outreach to 900 participants. The goal is to see if these approaches impr…

This study looks at the complete DNA and RNA of 10 people and their families who are at high risk for hereditary cancer but have no known genetic cause. Researchers will use whole genome sequencing and tumor analysis to discover new genetic changes that may lead to cancer. The go…

The IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…